1. Home
  2. TSN vs BIIB Comparison

TSN vs BIIB Comparison

Compare TSN & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyson Foods Inc.

TSN

Tyson Foods Inc.

N/A

Current Price

$57.45

Market Cap

23.4B

ML Signal

N/A

Logo Biogen Inc.

BIIB

Biogen Inc.

N/A

Current Price

$201.27

Market Cap

27.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TSN
BIIB
Founded
1935
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Meat/Poultry/Fish
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.4B
27.3B
IPO Year
1994
1996

Fundamental Metrics

Financial Performance
Metric
TSN
BIIB
Price
$57.45
$201.27
Analyst Decision
Buy
Buy
Analyst Count
10
25
Target Price
$66.90
$206.83
AVG Volume (30 Days)
2.5M
1.4M
Earning Date
05-04-2026
04-29-2026
Dividend Yield
3.21%
N/A
EPS Growth
N/A
N/A
EPS
0.97
2.15
Revenue
$54,441,000,000.00
$9,890,600,000.00
Revenue This Year
$5.74
N/A
Revenue Next Year
$1.14
N/A
P/E Ratio
$58.34
$93.31
Revenue Growth
2.12
2.22
52 Week Low
$50.56
$124.56
52 Week High
$69.48
$219.72

Technical Indicators

Market Signals
Indicator
TSN
BIIB
Relative Strength Index (RSI) 43.61 50.62
Support Level $55.24 $186.24
Resistance Level $59.35 $202.91
Average True Range (ATR) 0.95 8.46
MACD 0.03 -0.73
Stochastic Oscillator 26.52 55.87

Price Performance

Historical Comparison
TSN
BIIB

About TSN Tyson Foods Inc.

Tyson Foods is a protein-focused food producer, selling raw chicken, beef, pork, and prepared foods. Chicken and beef are its two largest segments, composing about 40% and 30% of sales, respectively. Prepared foods constituted 18% of fiscal 2025 sales and include brands like Tyson, Jimmy Dean, Hillshire Farm, Ball Park, and Sara Lee. However, most of these are in product categories rife with competition where Tyson does not have a massive market share lead. Tyson sells some products overseas, but the international segment accounts for just 4% of total revenue. The company is an active acquirer, with more recent years' purchases focused on international and food-service markets.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: